Sorafenib as maintenance therapy in FLT3+ acute myeloid leukemia post allogeneic transplantation: a case report.

IF 1.8 4区医学 Q3 ONCOLOGY

Anti-Cancer Drugs Pub Date : 2024-11-26 DOI:10.1097/CAD.0000000000001672

Alicia Martín Roldán, Carolina Alarcón-Payer, María Del Mar Sánchez Suárez, Alberto Jiménez Morales

引用次数: 0

Abstract

This case report highlights sorafenib as maintenance therapy postallogeneic hematopoietic stem cell transplantation (allo-HSCT) in a young patient with acute myeloid leukemia (AML) with FMS-like tirosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation. Given the high relapse risk in FLT3-ITD-positive AML, the tyrosine kinase inhibitor sorafenib was administered. Several studies have shown that sorafenib improves survival in younger AML patients when combined with chemotherapy, though side effects can limit use in older patients. Sorafenib is increasingly significant after allo-HSCT maintenance, offering a promising option for high-risk AML cases. In this case, the patient achieved long-term remission with minimal side effects.

查看原文本刊更多论文

索拉非尼作为同种异体移植后FLT3+急性髓性白血病的维持疗法：病例报告。

本病例报告重点介绍了索拉非尼作为异基因造血干细胞移植（allo-HSCT）后的维持疗法，用于一名患有FMS样酪氨酸激酶-3（FLT3）-内部串联重复（ITD）突变的急性髓性白血病（AML）的年轻患者。考虑到FLT3-ITD阳性急性髓细胞白血病的复发风险较高，患者接受了酪氨酸激酶抑制剂索拉非尼的治疗。多项研究表明，索拉非尼与化疗联合使用可提高年轻急性髓细胞白血病患者的生存率，但副作用会限制索拉非尼在老年患者中的使用。索拉非尼在allo-HSCT维持治疗后的意义越来越大，为高风险的AML病例提供了一个很有前景的选择。在本病例中，患者获得了长期缓解，且副作用极小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anti-Cancer Drugs 医学-药学

CiteScore

3.80

自引率

0.00%

发文量

244

审稿时长

3 months

期刊介绍： Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.